Mefloquine-oxazolidine derivatives: A new class of anticancer agents

Chemical Biology and Drug Design

Volumn 83, Issue 1, 2014, Pages 126-131

  Rodrigues, Felipe A R ^a   Bomfim, Igor Da S ^a   Cavalcanti, Bruno C ^a   Pessoa, Claudia ^a   Goncalves, Raoni S B ^b   Wardell, James L ^b,c   Wardell, Solange M S V ^d   De Souza, Marcus V N ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d CHEMSOL   (United Kingdom)

Author keywords

anticancer; antitumor activity; mefloquine; oxazolidine

Indexed keywords

4 [3 (ARYL)HEXAHYDRO[1,3]OXAZOLO[3,4 A]PYRIDIN 1 YL] 2,8 BIS(TRIFLUOROMETHYL)QUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; MEFLOQUINE; OXAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DAMAGE; CELL STRAIN HCT116; CELL STRAIN HL 60; CELL SUSPENSION; CONFORMATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG SCREENING; ELECTRON; ERYTHROCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANTICANCER; ANTITUMOR ACTIVITY; MEFLOQUINE; OXAZOLIDINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MEFLOQUINE; MOLECULAR CONFORMATION; OXAZOLES; QUINOLINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84891491584     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12210     Document Type: Article

References (20)

1. Kunin C.M., Ellis W.Y., (2000) Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob Agents Chemother; 44: 848-852.
2. Gonçalves R.S.B., Kaiser C.R., Lourenço M.C.S., Bezerra F.A.F.M., de Souza M.V.N., Wardell J.L., Wardell S.M.S.V., Henriques M.G.M.O., Costa T., (2012) Mefloquine oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: in vitro activity including against the multidrug-resistant tuberculosis strain T113. Bioorg Med Chem; 20: 243-248.
3. Gonçalves R.S.B., Kaiser C.R., Lourenço M.C.S., de Souza M.V.N., Wardell J.L., Wardell S.M.S.V., da Silva A.D., (2010) Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives. Eur J Med Chem; 45: 6095-6100.
4. Bermudez L.E., Kolonoski P., Wu M., Aralar P.A., Inderlied C.B., Young L.S., (1999) Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob Agents Chemother; 43: 1870-1874.
5. Carson D.A., Leoni L.M., Cottam H.B., inventors (2003) Regents of the University of California, assignee. Treatment of cancer with mefloquine, its purified enantiomers, and mefloquine analogs. United States patent US 20030216426.
6. Ingram K., Ellis W., Keiser J., (2012) Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother; 56: 3207-3215.
7. Schrattenholz A., inventor (2005) Proteosys A.-G., Germany, assignee. Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases. United States patent US 2005670648.
8. Seo J.B., Sun H.M., Choi S.S., Park D.Y., Park J.Y., Choi E.U., Jung J.Y., Shin D.S., Lee T.G., inventors (2012) BRNScience Co., Ltd., S. Korea, assignee. Mefloquine for preventing and treating bone disease. Republic Korean patent KR 2012045123.
9. Sharma N., Thomas S., Golden E.B., Hofman F.M., Chen T.C., Petasis N.A., Schonthal A.H., Louie S.G., (2012) Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett; 326: 143-154.
10. Shin J.H., Park S.J., Jo Y.K., Kim E.S., Kang H., Park J.H., Lee E.H., Cho D.H., (2012) Suppression of autophagy exacerbates mefloquine-mediated cell death. Neurosci Lett; 515: 162-167.
11. Ahmed S.A., Gogal R.M. Jr, Walsh J.E., (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods; 170: 211-224.
12. Sharma P., Sharma J.D., (2001) In vitro hemolysis of human erythrocytes-By plant extracts with antiplasmodial activity. J Ethnopharmacol; 74: 239-243.
13. Hooft R.W.W., (1998) COLLECT, Data Collection Software. Delft, The Netherlands: Nonius BV.
14. Sheldrick G.M., (2007) SADABS Version 2007/2. Madison, Wisconsin, USA: Bruker AXS Inc.
15. Otwinowski Z., Minor W. Jr,. (1997) Processing of X-ray diffraction data collected in oscillation mode. In:, Carter C.W., Sweet R.M., editors. Methods in Enzymology, Vol. 276: Macromolecular Crystallography, Part A. New York: Academic Press; p. 307-326.
16. Farrugia L.J., (1997) ORTEP-3 for Windows-a version of ORTEP-III with a Graphical User Interface (GUI). J Appl Crystallogr; 30: 565.
17. Sheldrick G.M., (2008) A short history of SHELX. Acta Crystallogr A; 64: 112-122.
18. Spek A.L., (2003) Single-crystal structure validation with the program PLATON. J Appl Crystallogr; 36: 7-13.
19. Gonçalves R.S.B., Kaiser C.R., de Souza M.V.N., Wardell J.L., Wardell S.M.S.V., Tiekink E.R.T., (2011) 2-{1-[2,8-Bis(trifluoromethyl)quinolin- 4-yl]-3,5,6,7,8,8a-hexahydro-1H-1,3-oxazolo[3,4-a]pyridin-3-yl}phenol. Acta Cryst; E67: o1656-o1657.
20. 2N), derived from mefloquine. Z Krist; 226: 793-803.